Scienture (SCNX, Financial) has announced the commencement of its supply chain activities for the manufacture of Arbli Oral Suspension, at a concentration of 10 mg/mL, in preparation for a commercial launch slated for July 2025. This initiative is being spearheaded by its wholly owned subsidiary, also named Scienture.
The company has partnered with Saptalis Pharmaceuticals to handle the production needs for Arbli. According to Saptalis, they possess both the necessary materials and capabilities to meet the production requirements and ensure the availability of the product inventory by the intended launch date.
Moreover, Scienture has secured agreements with strategic partners to facilitate the warehousing and distribution of Arbli Oral Suspension. These alliances are aimed at ensuring the product efficiently reaches the market via a network of various wholesalers.
